Compare IONQ Inc (IONQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs State Street SPDR S&P Biotech ETF — how do they compare? IONQ Inc trades at $35.49 (market cap $12.78B), while State Street SPDR S&P Biotech ETF trades at $153.23. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals.
| IONQ | XBI | |
|---|---|---|
Market Cap | $12.78B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $82.09 | $164.28 |
52-Week Low | $26.59 | $85.16 |
Enterprise Value | $10.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $34.24, down 1.55% with a bearish technical signal despite bullish oscillators. The company shows strong revenue growth projections from $130M in 2025 to $187M in 2026, but remains unprofitable with a net loss of $510M in 2025. Analyst consensus is split with a $73.75 price target representing 115% upside potential. Recent news highlights IonQ's leadership in quantum computing platform development and government validation.
The stock offers significant upside potential based on analyst targets but faces execution risks in achieving profitability. High valuation multiples (P/E 89.18, P/S 58.73) reflect growth expectations, while negative cash flow from operations and competitive threats in quantum computing present substantial risks for investors.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
